Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)- | 741241-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)-
• 英文别名: N'-methylsulfonyl-1-(2-oxo-2-thiophen-2-ylethyl)pyridin-1-ium-3-carbohydrazide
• CAS: 741241-58-7
• 化学式: C13H14N3O4S2+
• 分子量: 340.4
• InChiKey: SHRITMLAKAATEW-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] NOVEL PYRIDINIUM COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE PYRIDINIUM
  申请人：TORRENT PHARMACEUTICALS LTD

  公开号：WO2016162785A1

  公开（公告）日：2016-10-13

  The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.

  本发明涉及新型吡啶盐化合物，其异构体、立体异构体、对映异构体、构象体、互变异构体、多晶型、水合物和溶剂化合物。本发明还涵盖了制备新化合物的方法和所述化合物的药物组合物。该发明还涉及上述化合物用于制备用作药物的药物的用途。
• [EN] IN-SITU SYNTHESIS OF 3-SUBSTITUTED PYRIDINIUM COMPOUNDS<br/>[FR] SYNTHÈSE IN-SITU DE COMPOSÉS À BASE DE PYRIDINIUM 3-SUBSTITUÉS
  申请人：TORRENT PHARMACEUTICALS LTD

  公开号：WO2022238921A1

  公开（公告）日：2022-11-17

  Present invention relates to an in-situ and improved process for the preparation of 3-[2-(methylsulfonyl)hydrazinyl]carbonyl}- 1-[2-oxo-2- (thiophen-2-yl)ethyl]pyridinium salts or salt-cocrystal.

  本发明涉及一种原位改进的制备3-[2-(甲磺酰基)肼基]羰基}-1-[2-氧代-2-(噻吩-2-基)乙基]吡啶盐或盐-共晶的方法。
• Pyridinium compounds
  申请人：TORRENT PHARMACEUTICALS LIMITED

  公开号：US10233175B2

  公开（公告）日：2019-03-19

  The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.

  本发明涉及新型吡啶化合物、其异构体、拟异构体、构象体、同素异形体、多晶型体、水合物和溶解物。本发明还包括制备新型化合物的工艺和上述化合物的药物组合物。本发明还涉及使用上述化合物制备药物。
• Pharmaceutical formulations
  申请人：TORRENT PHARMACEUTICALS LIMITED

  公开号：US10772879B2

  公开（公告）日：2020-09-15

  This invention relates to pharmaceutical formulations comprising 1-(2-thien-2′-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2′-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof. The formulations of this invention are for treating diseases associated with advanced glycation end products.

  本发明涉及包含 1-(2-噻吩-2′-基-2-氧代-乙基)-3-(甲磺酰肼羰基)吡啶鎓、其药学上可接受的盐、盐晶体和共晶体，特别是 1-(2-噻吩-2′-基-2-氧代-乙基)-3-5(甲磺酰肼羰基)吡啶鎓氯化物的药物制剂。制剂适用于口服，还包括渗透性增强剂或合适的基质或其混合物。本发明的制剂用于治疗与高级糖化终产物有关的疾病。
• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。